The report also analyzes regional and application-specific markets, highlighting emerging sectors with high growth potential. It presents actionable recommendations and forecasts to guide strategic planning and investment decisions.
Cancer Supportive Care Products Market Size
- The global cancer supportive care products market size was valued at USD 21.66 billion in 2024 and is expected to reach USD 26.40 billion by 2032, at a CAGR of 2.50% during the forecast period
- This growth is driven by increasing cancer incidences
Access the full insights: https://www.databridgemarketresearch.com/reports/global-cancer-supportive-care-products-market
Cancer Supportive Care Products Market Analysis
- Cancer supportive care products play a crucial role in oncology by managing side effects of cancer treatments such as chemotherapy-induced nausea, neutropenia, anemia, and bone complications, thereby improving patients’ quality of life and adherence to primary therapies
- The demand for supportive care therapies is growing steadily due to the rising global cancer burden, increasing survival rates, and growing awareness of integrated cancer management approaches
- North America is expected to dominate the cancer supportive care products market with the largest market share of 48.87%, driven by a high prevalence of cancer, widespread adoption of advanced supportive therapies, robust healthcare spending, and strong regulatory frameworks
- Asia-Pacific is projected to witness the highest growth rate in the cancer supportive care products market during the forecast period, supported by rising cancer incidence, expanding healthcare access, increasing government healthcare spending, and growing adoption of biosimilars in emerging economies
- The granulocyte colony stimulating factor segment is expected to dominate the usability segment with the largest market share of 25.34% in 2025, as it serves as a frontline treatment for cancer-related neutropenia and is one of the most widely used supportive care therapies in the management of breast and lymphoma cancers
- The global increase in chemotherapy usage for various cancer types has led to a higher incidence of treatment-related complications such as neutropenia, anemia, and bone loss
- This surge in side effects is driving the demand for supportive care drugs such as G-CSF agents, erythropoiesis-stimulating agents, bisphosphonates, and antiemetics
- Hospitals and oncology centers are increasingly prioritizing prophylactic supportive therapies to reduce treatment delays and improve patient outcomes
- For instance, in 2024, the National Comprehensive Cancer Network (NCCN) updated its guidelines to recommend earlier use of growth factors during chemotherapy cycles for breast and lung cancer patients
- This driver is expected to continue supporting market growth by increasing the usage of preventive supportive care products in standard oncology protocols
- Acacia Pharma Group Plc (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Fagron (Belgium)
- KYOWA HAKKO BIO CO.,LTD. (Japan)
- APR (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Amgen Inc. (U.K.)
- Baxter (U.S.)
- Bayer AG (Germany)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
- GSK Plc (U.K.)
- In June 2023, the FDA approved the use of selumetinib (Koselugo) for treating patients with metastatic melanoma that has progressed after previous therapies. Selumetinib functions as a MEK inhibitor, targeting pathways that drive cancer cell proliferation. This approval expands the treatment options available for late-stage melanoma patients facing limited alternatives
- In May 2023, the FDA granted approval for denosumab (Prolia) to be used in the prevention of bone loss among breast cancer patients receiving aromatase inhibitors. Denosumab, a monoclonal antibody, works by blocking the RANKL protein, which is associated with bone degradation. This decision supports bone health preservation in patients undergoing hormonal cancer therapies
- In April 2023, the FDA authorized the use of pembrolizumab (Keytruda) for the treatment of advanced solid tumors that have progressed despite prior therapies. Pembrolizumab is a checkpoint inhibitor that disrupts the PD-1/PD-L1 interaction, thereby enhancing the immune system's ability to target cancer cells. This broadens the clinical application of immunotherapy in resistant solid tumor cases
- In March 2022, Novartis received FDA approval for Pluvicto, a therapy for metastatic castration-resistant prostate cancer (mCRPC) patients with PSMA-positive tumors who had already undergone hormone and chemotherapy treatments. Pluvicto offers a new avenue of treatment for patients with advanced stages of prostate cancer
- In March 2022, Australian biotech firm Imugene entered into a collaboration with MSD (Merck & Co., Inc.) to evaluate the combination of HER-Vaxx, a B-cell activating immunotherapy, with KEYTRUDA (pembrolizumab) in HER-2 positive gastric cancer patients. This clinical trial aims to explore the safety and efficacy of combining immunotherapies for enhanced treatment outcomes
- In June 2020, copyright Inc. announced that the FDA approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta, designed to reduce the risk of infection due to febrile neutropenia in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. This biosimilar expands access to supportive care therapies critical in cancer treatment cycles
Key Report Highlights
Market Size and Growth Forecasts
Emerging Trends and Innovation Drivers
Competitive Landscape and Major Players
Segmentation by Product, Application, and Geography
Consumer Insights and Behavior
Regional Market Performance
Report Contents
Introduction and Research Objectives
Market Overview and Dynamics
Segmentation and Forecast Analysis
Competitive Assessment
Strategic Recommendations
Regional Insights
Future Outlook
Browse More Reports:
Global Dental Carpule Market
Global Dental Connected Technology Solutions Market
Global Dental Crowns and Bridges Market
Global Dental Digital X-Ray Market
Global Diameter Signaling Market
Global Diesel Exhaust Fluid Market
Global Differential Diagnostics Market
Global Digestive Health Food and Drinks Market
Global Digital Calipers with LED Display Market
Global Digital Education Content Market
Global Digital Light Processing Technology Market
Global Digital Process Automation Market
Global Dilators Market
Global Dimer Acid Market
Global Disc Plough Blades Market
Global Display Optical Film Market
Global Display Quantum Dots Market
Global Distillation System in Food Applications Market
Global Diving Compressor Market
Global DNA Fragmentation Technique Market
About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +653 1251 975
Email: [email protected]